| 2.55 -0.07 (-2.68%) | 04-26 09:33 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.33 | 1-year : | 3.58 |
| Resists | First : | 2.85 | Second : | 3.06 |
| Pivot price | 2.68 |
|||
| Supports | First : | 2.5 | Second : | 2.08 |
| MAs | MA(5) : | 2.59 |
MA(20) : | 2.72 |
| MA(100) : | 3.03 |
MA(250) : | 3.64 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 20.6 |
D(3) : | 24.9  |
| RSI | RSI(14): 35 |
|||
| 52-week | High : | 5.59 | Low : | 2.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PMD ] has closed above bottom band by 21.0%. Bollinger Bands are 20.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.64 - 2.66 | 2.66 - 2.67 |
| Low: | 2.51 - 2.52 | 2.52 - 2.53 |
| Close: | 2.52 - 2.54 | 2.54 - 2.56 |
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.
Thu, 28 Mar 2024
Psychemedics Corporation Reports 2023 Financial Results - Yahoo Finance
Thu, 21 Mar 2024
Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider - GlobeNewswire
Tue, 02 Jan 2024
Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas - Yahoo Finance
Fri, 11 Aug 2023
EdgarFiling - SEC.gov
Tue, 21 Mar 2023
Psychemedics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Declares Quarterly Cash ... - GlobeNewswire
Wed, 17 Mar 2021
Robyn C. Davis Joins Psychemedics Board of Directors - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 6 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 22.7 (%) |
| Held by Institutions | 22.3 (%) |
| Shares Short | 16 (K) |
| Shares Short P.Month | 12 (K) |
| EPS | -0.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.14 |
| Profit Margin | -18.8 % |
| Operating Margin | -17.4 % |
| Return on Assets (ttm) | -11.8 % |
| Return on Equity (ttm) | -47.7 % |
| Qtrly Rev. Growth | -12.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.8 |
| EBITDA (p.s.) | -0.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -3.53 |
| PEG Ratio | 0 |
| Price to Book value | 2.2 |
| Price to Sales | 0.66 |
| Price to Cash Flow | -9.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|